Histone Deacetylase Inhibitors: Overview and Perspectives

Histone deacetylase inhibitors (HDACi) comprise structurally diverse compounds that are a group of targeted anticancer agents. The first of these new HDACi, vorinostat (suberoylanilide hydroxamic acid), has received Food and Drug Administration approval for treating patients with cutaneous T-cell lymphoma. This review focuses on the activities of the 11 zinc-containing HDACs, their histone and nonhistone protein substrates, and the different pathways by which HDACi induce transformed cell death. A hypothesis is presented to explain the relative resistance of normal cells to HDACi-induced cell death. (Mol Cancer Res 2007;5(10):981–9)

[1]  C. Van Lint,et al.  The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. , 1996, Gene expression.

[2]  Wen‐Ming Yang,et al.  Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  P. Marks,et al.  A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Schreiber,et al.  Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Y. Hayashi,et al.  MLL‐CBP fusion transcript in a therapy‐related acute myeloid leukemia with the t(11;16)(q23;p13) which developed in an acute lymphoblastic leukemia patient with Fanconi anemia , 2000 .

[6]  W. D. Cress,et al.  Histone deacetylases, transcriptional control, and cancer , 2000, Journal of cellular physiology.

[7]  Tony Kouzarides,et al.  Acetylation of importin-α nuclear import factors by CBP/p300 , 2000, Current Biology.

[8]  D. Fairlie,et al.  Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. , 2000, Molecular biology of the cell.

[9]  T. Kouzarides,et al.  Regulation of E2F1 activity by acetylation , 2000, The EMBO journal.

[10]  Y. Hayashi,et al.  MLL-CBP fusion transcript in a therapy-related acute myeloid leukemia with the t(11;16)(q23;p13) which developed in an acute lymphoblastic leukemia patient with Fanconi anemia. , 2000, Genes, chromosomes & cancer.

[11]  T. Yamagata,et al.  Acetylation of GATA‐3 affects T‐cell survival and homing to secondary lymphoid organs , 2000, The EMBO journal.

[12]  S. Tsuzuki,et al.  Histone deacetylase 3 associates with and represses the transcription factor GATA-2. , 2001, Blood.

[13]  R. Schiltz,et al.  A role for histone deacetylase HDAC1 in modulating the transcriptional activity of MyoD: inhibition of the myogenic program , 2001, The EMBO journal.

[14]  B. Johansson,et al.  Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). , 2001, Human molecular genetics.

[15]  B. Katzenellenbogen,et al.  Direct Acetylation of the Estrogen Receptor α Hinge Region by p300 Regulates Transactivation and Hormone Sensitivity* , 2001, The Journal of Biological Chemistry.

[16]  A. Means,et al.  The Modular Nature of Histone Deacetylase HDAC4 Confers Phosphorylation-dependent Intracellular Trafficking* , 2001, The Journal of Biological Chemistry.

[17]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[18]  R. Marmorstein.  Structure of histone acetyltransferases. , 2001, Journal of molecular biology.

[19]  D. O’Carroll,et al.  Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression , 2002, The EMBO journal.

[20]  Chun Li Zhang,et al.  Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy , 2002, Cell.

[21]  E. Miska,et al.  Acetylation of β-Catenin by CREB-binding Protein (CBP)* , 2002, The Journal of Biological Chemistry.

[22]  Colin A. Johnson,et al.  Human Class I Histone Deacetylase Complexes Show Enhanced Catalytic Activity in the Presence of ATP and Co-immunoprecipitate with the ATP-dependent Chaperone Protein Hsp70* , 2002, The Journal of Biological Chemistry.

[23]  David E Neal,et al.  Tip60 and Histone Deacetylase 1 Regulate Androgen Receptor Activity through Changes to the Acetylation Status of the Receptor* , 2002, The Journal of Biological Chemistry.

[24]  Moon-Kyoung Bae,et al.  Regulation and Destabilization of HIF-1α by ARD1-Mediated Acetylation , 2002, Cell.

[25]  M. Bustin,et al.  Modulation of HMG‐N2 binding to chromatin by butyrate‐induced acetylation in human colon adenocarcinoma cells , 2002, International journal of cancer.

[26]  M. Gray,et al.  DNA Damage-induced Translocation of the Werner Helicase Is Regulated by Acetylation* , 2002, The Journal of Biological Chemistry.

[27]  G. Blandino,et al.  DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. , 2002, Molecular cell.

[28]  Wei Gu,et al.  Acetylation inactivates the transcriptional repressor BCL6 , 2002, Nature Genetics.

[29]  Xiao-Fan Wang,et al.  HDAC6 is a microtubule-associated deacetylase , 2002, Nature.

[30]  Leslie M Thompson,et al.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  B. Schuettengruber,et al.  Autoregulation of Mouse Histone Deacetylase 1 Expression , 2003, Molecular and Cellular Biology.

[32]  W. Greene,et al.  Regulation of distinct biological activities of the NF-κB transcription factor complex by acetylation , 2003, Journal of Molecular Medicine.

[33]  Paul Dent,et al.  The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. , 2003, Blood.

[34]  Stuart L Schreiber,et al.  Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Wolfgang Fischle,et al.  Binary switches and modification cassettes in histone biology and beyond , 2003, Nature.

[36]  T. Naoe,et al.  Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation , 2003, Oncogene.

[37]  L. Schwartz,et al.  Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  L. Ngo,et al.  Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  John M. Shelton,et al.  Histone Deacetylase 4 Controls Chondrocyte Hypertrophy during Skeletogenesis , 2004, Cell.

[40]  Susan M. Chang,et al.  A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors , 2003, Investigational New Drugs.

[41]  E. Seto,et al.  Regulation of histone deacetylase activities , 2004, Journal of cellular biochemistry.

[42]  N. Bertos,et al.  Role of the Tetradecapeptide Repeat Domain of Human Histone Deacetylase 6 in Cytoplasmic Retention* , 2004, Journal of Biological Chemistry.

[43]  Minoru Yoshida,et al.  Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. , 2004, Bioorganic & Medicinal Chemistry Letters.

[44]  Hidde Ploegh,et al.  Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. , 2004, Molecular cell.

[45]  Stephen R James,et al.  Acetylation of insulin receptor substrate-1 is permissive for tyrosine phosphorylation , 2004, BMC biology.

[46]  M. Benkirane,et al.  Regulation of human SRY subcellular distribution by its acetylation/deacetylation , 2004, The EMBO journal.

[47]  Marie Joseph,et al.  Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[48]  B. Sarg,et al.  In vitro acetylation of HMGB-1 and -2 proteins by CBP: the role of the acidic tail. , 2004, Biochemistry.

[49]  D. Birnbaum,et al.  Variant MYST4‐CBP gene fusion in a t(10;16) acute myeloid leukaemia , 2004, British journal of haematology.

[50]  K. Furge,et al.  Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. , 2004, International journal of oncology.

[51]  Ivan V. Gregoretti,et al.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.

[52]  U. Germing,et al.  Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. , 2004, Blood.

[53]  D. Nguyen,et al.  Acetylation regulates the differentiation‐specific functions of the retinoblastoma protein , 2004, The EMBO journal.

[54]  Yu-Chung Yang,et al.  Sumoylation and Acetylation Play Opposite Roles in the Transactivation of PLAG1 and PLAGL2* , 2005, Journal of Biological Chemistry.

[55]  Y. E. Chin,et al.  Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue , 2005, Science.

[56]  E. Seto,et al.  Acetylation and deacetylation of non-histone proteins. , 2005, Gene.

[57]  C. Monneret,et al.  Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.

[58]  M. Dokmanovic,et al.  Prospects: Histone deacetylase inhibitors , 2005, Journal of cellular biochemistry.

[59]  G. Stamatoyannopoulos,et al.  Hydroxamide derivatives of short-chain fatty acid have erythropoietic activity and induce gamma gene expression in vivo. , 2005, Experimental hematology.

[60]  Y. Ning,et al.  Detection of MOZ-CBP fusion in acute myeloid leukemia with 8;16 translocation , 2005, Leukemia.

[61]  G. Fantuzzi,et al.  The Histone Deacetylase Inhibitor ITF2357 Reduces Production of Pro-Inflammatory Cytokines In Vitro and Systemic Inflammation In Vivo , 2005, Molecular medicine.

[62]  K. Gelmon,et al.  Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors , 2005 .

[63]  Gordon K Smyth,et al.  Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[64]  K. E. Elagib,et al.  AML-1-ETO-Mediated erythroid inhibition: new paradigms for differentiation blockade by a leukemic fusion protein. , 2005, Critical reviews in eukaryotic gene expression.

[65]  Maria Simonsson,et al.  The Balance between Acetylation and Deacetylation Controls Smad7 Stability* , 2005, Journal of Biological Chemistry.

[66]  Minoru Yoshida,et al.  HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. , 2005, Molecular cell.

[67]  C. Horvath,et al.  Unexpected roles for deacetylation in interferon- and cytokine-induced transcription. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[68]  S. Grant,et al.  Histone deacetylase inhibitors: insights into mechanisms of lethality , 2005, Expert opinion on therapeutic targets.

[69]  B. Linggi,et al.  Translating the histone code into leukemia , 2005, Journal of cellular biochemistry.

[70]  S. Nemoto,et al.  SIRT1 Functionally Interacts with the Metabolic Regulator and Transcriptional Coactivator PGC-1α* , 2005, Journal of Biological Chemistry.

[71]  J. Routy.  Valproic acid: a potential role in treating latent HIV infection , 2005, The Lancet.

[72]  D. Markovitz,et al.  p300/CBP-associated Factor Drives DEK into Interchromatin Granule Clusters* , 2005, Journal of Biological Chemistry.

[73]  J. Nicolas,et al.  SHP represses transcriptional activity via recruitment of histone deacetylases. , 2005, Biochemistry.

[74]  E. Olson,et al.  Protein Kinase D1 Phosphorylates HDAC7 and Induces Its Nuclear Export after T-cell Receptor Activation* , 2005, Journal of Biological Chemistry.

[75]  G. Perez,et al.  Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[76]  L. Schwartz,et al.  Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  C. Horvath,et al.  Positive and Negative Regulation of the Innate Antiviral Response and Beta Interferon Gene Expression by Deacetylation , 2006, Molecular and Cellular Biology.

[78]  Ju-Hee Lee,et al.  Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells , 2006, Molecular Cancer Therapeutics.

[79]  L. Aaltonen,et al.  A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition , 2006, Nature Genetics.

[80]  I. Adcock,et al.  Histone deacetylase 2–mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression , 2006, The Journal of experimental medicine.

[81]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[82]  T. Yao,et al.  Histone deacetylase 3 binds to and regulates the GCMa transcription factor , 2006, Nucleic acids research.

[83]  S. Fortuni,et al.  Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors , 2006, Nature Medicine.

[84]  G. Perez,et al.  Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor , 2006, Proceedings of the National Academy of Sciences.

[85]  Minghong Xu,et al.  Histone Deacetylase 3 Interacts with and Deacetylates Myocyte Enhancer Factor 2 , 2006, Molecular and Cellular Biology.

[86]  P. Wong,et al.  Acetylation and deacetylation of non-histone proteins , 2006 .

[87]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[88]  Andrew J. Wilson,et al.  Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer* , 2006, Journal of Biological Chemistry.

[89]  E. Olson,et al.  Histone Deacetylase 7 Maintains Vascular Integrity by Repressing Matrix Metalloproteinase 10 , 2006, Cell.

[90]  Y. Bang,et al.  Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.

[91]  G. Bates,et al.  Histone deacetylase inhibitors as therapeutics for polyglutamine disorders , 2006, Nature Reviews Neuroscience.

[92]  L. Schwartz,et al.  Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. , 2006, Clinical lung cancer.

[93]  Chunlei Zhang,et al.  Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.

[94]  W. Wurst,et al.  Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity , 2007, Nature Medicine.

[95]  K. Harms,et al.  Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. , 2007, Cancer research.

[96]  P. Romagnani,et al.  Pharmacological modulation of stem cell function. , 2007, Current medicinal chemistry.

[97]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[98]  N. Rosen,et al.  An acetylation site in the middle domain of Hsp90 regulates chaperone function. , 2007, Molecular cell.

[99]  Li-Huei Tsai,et al.  Recovery of learning and memory is associated with chromatin remodelling , 2007, Nature.

[100]  Ronald Breslow,et al.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.

[101]  Yoshiharu Kawaguchi,et al.  HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions , 2007, Journal of Cell Science.

[102]  G. Perez,et al.  Histone deacetylase inhibitors selectively suppress expression of HDAC7 , 2007, Molecular Cancer Therapeutics.

[103]  Kyu-Won Kim,et al.  Regulation of the HIF-1α stability by histone deacetylases , 2007 .

[104]  Tao Liu,et al.  Design and synthesis of a potent histone deacetylase inhibitor. , 2007, Journal of medicinal chemistry.

[105]  R. Baron,et al.  Anti‐rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen‐induced arthritis in rodents , 2007, British journal of pharmacology.

[106]  V. Richon,et al.  Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[107]  S. Szabo,et al.  Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. , 2007, Blood.

[108]  A. El-Osta,et al.  Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? , 2007, Leukemia.

[109]  James M. Morrell,et al.  Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. , 2007, Bioorganic & medicinal chemistry letters.

[110]  S. Grünewald,et al.  Factors affecting the substrate specificity of histone deacetylases. , 2007, Biochemical and biophysical research communications.

[111]  I. Adcock.  HDAC inhibitors as anti‐inflammatory agents , 2007, British journal of pharmacology.

[112]  T. Mahmoudi,et al.  Myosin phosphatase dephosphorylates HDAC7, controls its nucleocytoplasmic shuttling, and inhibits apoptosis in thymocytes. , 2007, Genes & development.

[113]  S. Bates,et al.  Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy , 2007, Cancer journal.